Clinical Trial Update: GM-CSF to Decrease ICU Acquired Infections [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating GM-CSF to decrease ICU-acquired infections has completed in patients with septic shock and sepsis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Septic Shock, Severe Sepsis | Phase 3 | Status: COMPLETED